GlassScriptPhysician profile
Monica Wang
NPI 1285049569
$4,017.54
in general payments reported to CMS, 2019-2025
32 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $46.45 · 2021: $309 · 2022: $534 · 2023: $743 · 2024: $867 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.63 | 2022-2025 | Durysta, Ozurdex, Lumigan |
| Regeneron Healthcare Solutions, INC. | $524.38 | 2019-2025 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $308.15 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $233.42 | 2022-2025 | Xipere, Visudyne, Vyzulta |
| New World Medical,INC. | $212.03 | 2025 | Clearpath, Via360, Streamline |
| Alcon Vision LLC | $143.94 | 2021-2025 | Tryptyr, Rocklatan, Simbrinza |
| Sun Pharmaceutical Industries INC. | $136.70 | 2019-2025 | Cequa |
| Allergan, INC. | $135.09 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $128.63 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Coopervision INC. | $99.14 | 2021 | |
| Astellas Pharma US INC | $80.71 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $79.86 | 2019-2022 | |
| Harrow Eye, LLC | $75.00 | 2024-2025 | Vevye |
| Eyepoint US, INC. | $74.41 | 2022 | |
| Dompe US, INC. | $65.52 | 2025 | Oxervate |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $56.50 | 2024-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $53.51 | 2025 | Syfovre |
| Shire North American Group INC | $48.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $35.35 | 2020-2021 | |
| Coherus Oncology, INC. | $33.13 | 2024 | |
| Amgen INC. | $32.42 | 2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $28.59 | 2025 | Acthar |
| Biotissue Holdings INC. | $25.58 | 2023 | |
| Sandoz INC. | $23.56 | 2024 | Cimerli |
| Rayner Intraocular Lenses Limited | $20.63 | 2022 | |
| Alimera Sciences, INC. | $17.99 | 2024 | Iluvien, Yutiq |
| Thea Pharma INC. | $16.62 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.39 | 2021 | |
| Alcon Research LLC | $14.38 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $13.77 | 2025 | Tecnis Iol, Tecnis Simplicity |
| Horizon Therapeutics Plc | $11.71 | 2022 | |
| Vyera Pharmaceuticals, LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.